The Pharma Letter M&A roundup - July 2023

4 August 2023

US biotech Biogen (Nasdaq: BIIB) announced a major M&A deal in July, with Eli Lilly (NYSE: LLY) and Novartis (NOVN: VX) the other big biopharma companies to unveil acquisitions during the month.

It was another healthy month of overall spending in the sector, keeping 2023's running total way ahead of the sums from the same time in 2022 and 2021.

Due to its $43 billion takeover of Seagen, US pharma giant Pfizer (NYSE: PFE) has spent as much in pharma M&A this year as all of the other top 50 firms combined

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK